🔎 Trials Near Me

Hjem › Burkitts lymfom › Nevada

Kliniske studier for Burkitts lymfom i Nevada

6 studier for Burkitts lymfom søker deltakere på steder i Nevada.

Byer i Nevada

Offisiell studietekst (engelsk)

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

  • OptumCare Cancer Care at Charleston, Las Vegas
  • OptumCare Cancer Care at Fort Apache, Las Vegas
RekruttererFase 3
Alder 18 til 39 · Alle kjønn · Oppdatert 2. okt. 2026 · NCT03150693

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

  • OptumCare Cancer Care at Charleston, Las Vegas
  • OptumCare Cancer Care at Fort Apache, Las Vegas
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 29. sep. 2026 · NCT03739814

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

  • Alliance for Childhood Diseases/Cure 4 the Kids Foundation, Las Vegas
RekruttererFase 2
365 Days · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06317662

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

  • Alliance for Childhood Diseases/Cure 4 the Kids Foundation, Las Vegas
  • Summerlin Hospital Medical Center, Las Vegas
  • Renown Regional Medical Center, Reno
RekruttererFase 2
Alder 1 til 30 · Alle kjønn · Oppdatert 1. sep. 2026 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  • Alliance for Childhood Diseases/Cure 4 the Kids Foundation, Las Vegas
  • Summerlin Hospital Medical Center, Las Vegas
  • Renown Regional Medical Center, Reno
RekruttererFase 3
365 Days – 25 Years · Alle kjønn · Oppdatert 25. aug. 2026 · NCT03959085

Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.